About this trial
In recent years, researches illustrate that multifactorial diseases such as functional gastrointestinal disorders, autoimmune diseases, metabolic, behavioral and neurological diseases are associated with an abnormal microbiome structure-dysbiosis, which means the imbalance of the microbiome community. Fecal microbiota transplantation (FMT), the infusion of faeces from a healthy donor to the gastrointestinal tract of a recipient patient aiming to alter the intestine microbiota, is recommended to be performed in Clostridium difficile infection(CDI) as the most effective therapy. It also being used experimentally in the treatment of the disease states linked to dysbiosis of the intestinal microbiota. However, the efficacy and safety of FMT to treat the dysbiosis-associated diseases is still in its infancy. To further verify the indications above, more data is required to be collected through studies.
Eligibility criteria
Qualifiers
Irritable Bowel Syndrome
Ulcerative colitis
Crohn's disease
Constipation
Disqualifiers
Current pregnancy or breast-feeding;
Suffering from other severe diseases, including liver or kidney failure, heart failure, MODS, coma, cerebrovascular accident;
Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, endoscopy, colonoscopy and enema;
Any conditions that may render the efficacy of FMT or at the discretion of the investigators.
Trial design
Treatments tested in this trial
- Fecal Microbiota Transplantation
Treatment groups
40
Treatment groupsSee each treatment group below.